Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct;20(5):271-285.
doi: 10.1007/s11904-023-00665-x. Epub 2023 Sep 21.

The New Era of Long-Acting Antiretroviral Therapy: When and Why to Make the Switch

Melanie C Goebel  1 , Emmanuel Guajardo  2   3 , Thomas P Giordano  4   5 , Shital M Patel  4
Affiliations
Review

The New Era of Long-Acting Antiretroviral Therapy: When and Why to Make the Switch

Melanie C Goebel et al. Curr HIV/AIDS Rep. 2023 Oct.

Abstract

Purpose of review: Despite the availability of safe and effective oral combination antiretroviral therapy, barriers to maintaining viral suppression remain a challenge to ending the HIV epidemic. Long-acting injectable antiretroviral therapy was developed as an alternative to daily oral therapy. This review summarizes the current literature on the efficacy of long-acting cabotegravir plus rilpivirine for the treatment of HIV-1, reasons to switch to injectable therapy, and barriers to switching.

Recent findings: Long-acting cabotegravir plus rilpivirine is safe and effective in maintaining HIV-1 virologic suppression. Ideal candidates for switching to long-acting cabotegravir plus rilpivirine are virologically suppressed on oral regimens with good adherence and no history of virologic failure or baseline resistance. Indications to switch to injectable therapy include patient preference, the potential for improved adherence, and avoidance of adverse effects. Implementation research is needed to assess and overcome system barriers. Long-acting cabotegravir plus rilpivirine is a novel alternative to oral antiretrovirals, with the potential to improve adherence and quality of life in people with HIV.

Keywords: Cabotegravir-rilpivirine; HIV-1 treatment; Long-acting antiretroviral therapy; Patient preference; System barriers.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Shubber Z, Mills EJ, Nachega JB, Vreeman R, Freitas M, Bock P, et al. Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis. PLoS Med. 2016;13(11):e1002183. https://doi.org/10.1371/journal.pmed.1002183 . - DOI - PubMed - PMC
    1. Centers for Disease Control and Prevention: Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2019. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html (2021). Accessed February 10, 2023.
    1. Centers for Disease Control and Prevention. Ending the HIV Epidemic in the U.S. (EHE). https://www.cdc.gov/endhiv/treat.html . Accessed 10 Feb 2023.
    1. ViiV Healthcare: Cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension (Cabenuva) [package insert]. U.S. Food and Drug Administration Website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212888s005s006... Accessed April 13, 2023.
    1. Hodge D, Back DJ, Gibbons S, Khoo SH, Marzolini C. Pharmacokinetics and drug-drug interactions of long-acting intramuscular cabotegravir and rilpivirine. Clin Pharmacokinet. 2021;60(7):835–53. https://doi.org/10.1007/s40262-021-01005-1 . - DOI - PubMed - PMC

LinkOut - more resources